Local Manufacturing Strategy and Fee Advantages for Medical Devices in Kenya
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Content verification date: October 30, 2026
1. Key takeaways
- The Kenya Ministry of Health is advancing the Kenya Health Products and Technologies Local Manufacturing Strategy 2026–2030, a policy document sourced from public reporting and treated by GRZAN as a practical estimate.
- The fee advantage is already in current documents. Table 6 of the Guidelines (HPT/PER/HTR/GUD/011) sets registration fees for imported products at Class A USD 100, Class B USD 200, Class C and D USD 1,000 each; for locally manufactured products, Class A USD 50, Class B USD 50, Class C and D USD 100 each. The Class C/D gap reaches 10 times.
- Two fee scales coexist and must be stated honestly: the Second Schedule of LN 100 of 2022 lists registration applications for health products not manufactured in Kenya at USD 1,000 and Kenyan-made at USD 500, the same amounts for renewal; that Schedule does not distinguish device classes and does not list annual retention or variation fees. Table 6 does distinguish. Actual charging follows the PRIMS system.
- The long-run gap is wider. Under the imported scale, annual retention fees are Class A and B USD 50 and Class C and D USD 300; under the locally manufactured scale a flat USD 50. The variation fee is USD 200 for imports and USD 50 locally.
- Local manufacturing has two preconditions: a manufacturing licence under section 35A of Cap. 244, and establishment registration under the Guidelines for Registration of Medical Devices Establishments (PRA/LPP/GUD/072); a manufacturer’s certificate is valid for 5 years after successful re-inspection, while a general establishment certificate expires each December 31.
2. Legal basis
| Regulation | Reference / number | Date issued / effective | Provisions | Points relevant to this article |
|---|---|---|---|---|
| Kenya Health Products and Technologies Local Manufacturing Strategy 2026–2030 | — (policy announcement, not a statutory provision) | Advanced from 2026 | — (policy announcement, not a statutory provision) | Source is a public statement by the Ministry of Health (public reporting, practical estimate); promotes local manufacturing of health products and technologies, forming a policy package with falsified product governance and traceability |
| Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 | Legal Notice No. 100 of 2022 | Made on June 8, 2022 | Second Schedule, Rules 5(4) and 4(3)(l) | Registration applications and renewal for products not manufactured in Kenya at USD 1,000 each; Kenyan-made at USD 500 each; a valid licence under s.9A, s.27, s.28, s.32 or s.35A is required before a certificate is issued |
| Guidelines for Registration of Medical Devices including In-Vitro Diagnostics | HPT/PER/HTR/GUD/011, Rev.02 | Effective January 31, 2022; review due January 1, 2027 | Table 6, Section 2.11 | Two fee scales for imported and locally manufactured products; annual retention and variation fee scales; retention runs by calendar year and the annual fee is non-refundable |
| Pharmacy and Poisons Act | Cap. 244, Laws of Kenya | Enacted in 1957 (as amended several times) | Sections 35A and 41 | Manufacturing licence; labelling requirements |
| Guidelines for Registration of Medical Devices Establishments | PRA/LPP/GUD/072 | — | Dossier list | A quality manual, QMS procedures, official contact person declarations and the full list of imported devices must be submitted; PPB conducts an on-site inspection; manufacturer certificates are valid for 5 years after re-inspection |
3. Expert insights
Insight 1: the 10-fold Class C/D fee gap is Kenya’s most direct industrial policy signal
Put the two columns side by side: Class A from USD 100 to USD 50, Class B from USD 200 to USD 50, Class C and D from USD 1,000 to USD 100. GRZAN’s judgement: the gradient is not arbitrary; the discount grows with risk class, showing the policy targets local production of high-value devices, not low-value consumables. For companies with assembly or packaging capability in East Africa, or planning a plant, the Class C/D gap can offset part of the localisation investment over several product cycles. Note the precondition: the local rate requires a manufacturing licence under section 35A of Cap. 244, and simple import-then-repack does not constitute local manufacturing.
Insight 2: with two fee scales coexisting, budget on the more conservative one
The Second Schedule of LN 100 of 2022 lists USD 1,000 for products not manufactured in Kenya and USD 500 for Kenyan-made products; Table 6 sets class-specific scales for imported and locally manufactured products. The two do not fully agree: the Second Schedule does not distinguish device classes and does not list class-specific retention or variation fees. GRZAN recommends budgets list both scales and reserve at the higher figure, settling at the actual PRIMS charge. Payment timing also affects cash flow: the application fee is paid at submission and the evaluation fee on acceptance for evaluation; the application fee is non-refundable once successfully submitted and the evaluation fee non-refundable once accepted, whether withdrawn or rejected.
Insight 3: the real cost advantage lies in the long-run retention and variation items
Registration fees are one-off; retention fees recur every year. On the imported scale, annual retention for Class C/D is USD 300 against USD 50 for local manufacturing, a 6-fold gap; variation fees are USD 200 for imports and USD 50 locally, a 4-fold gap. For companies with many lines and frequent changes, the cumulative long-run difference exceeds the registration fee itself. GRZAN notes annual retention also carries procedural risk: Section 2.11 provides that retention runs by calendar year, the annual fee is non-refundable, the system opens 60 days before the due date, and non-payment can lead to suspension and revocation. The local manufacturing fee advantage is only realised with unbroken retention continuity.
Insight 4: the real threshold of local manufacturing is the on-site inspection and the document system
Fees are the entry; the threshold comes after. The establishment guidelines (PRA/LPP/GUD/072) require a copy of the quality manual, the established QMS, official contact person declarations that complaint handling, FSCA, and substandard and falsified product handling and disposal procedures are documented, authorised representative declarations that handling, storage, delivery, installation, corrective action and servicing procedures are documented, and the full list of devices imported into Kenya; PPB conducts document review and an on-site inspection. GRZAN notes local manufacturing is not a relabelling of the certificate: it means an on-site inspection as demanding as, or stricter than, an importer’s. A manufacturer’s certificate is valid for 5 years after successful re-inspection, and re-inspection itself includes an on-site inspection.
4. Practical recommendations
- Compute total cost of ownership before deciding. GRZAN recommends modelling registration fees, annual retention, variation fees and localisation investment together, comparing imported and local routes over a 5-year horizon.
- Confirm the recognition standard for local manufacturing. Before investing, obtain PPB’s written confirmation of whether the intended processes, such as assembly, packaging, sterilisation or full production, constitute local manufacturing.
- File the manufacturing licence and establishment registration in parallel. The section 35A licence under Cap. 244 is a precondition for issuing the registration certificate; advance both together.
- Budget on the most conservative scale. List both the Second Schedule and Table 6 figures, reserve at the higher, and settle at the actual PRIMS charge.
- Front-load on-site inspection preparation. Finalise the quality manual, QMS procedures and six declarations before applying; do not wait for the inspection notice.
- Put retention continuity in the finance calendar. Set calendar-year reminders and start 90 days before the due date, so unpaid fees never trigger suspension and revocation.
5. Verification checklist
- □ Has total cost of ownership of the imported and local routes been compared over a 5-year horizon?
- □ Has PPB confirmed in writing that the intended local processes constitute local manufacturing?
- □ Are the Cap. 244 s.35A manufacturing licence and establishment registration advancing in parallel?
- □ Does the fee budget list both the Second Schedule and Table 6 scales?
- □ Are the quality manual, QMS procedures and the six declarations documented before application?
- □ Are the six inspection areas ready: complaints, FSCA, falsified product disposal, handling, storage and delivery?
- □ Is annual retention in the finance calendar with calendar-year reminders?
Regulatory information verified as of October 30, 2026.
In African markets, the GRZAN regulatory team focuses on Kenya, Nigeria, South Africa and Egypt and verifies every published regulatory conclusion against official gazettes, competent authority guidelines and public legal databases, with the verification date marked; figures, cycles and amounts not locatable in official sources are marked as practical estimates, not presumed.
GRZAN services cover market access strategy and risk classification; preparation and review of dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); QMS and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and compliance ledgers.
For local manufacturing feasibility, fee modelling and inspection readiness in Kenya, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us